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Poster Session I 79limited to skin, and limited chronic oral GVHD. Neither patient
developed EBV-PTLPD. CD31CD41 . 400/mm3 was achieved
by days1174 and1307, and each patient exhibited normalmitogen
responses to phytohemagglutinin and pokeweed by days 1275 and
1384. Vaccine responses to diphtheria and tetanus were noted in
the patient in whom titers were studied. There were no unexpected
toxicities related to the HSCT procedure, and both patients remain
alive greater than one year after HSCT with Lansky scores of 100.
Both are 100%donor chimerism byVNTR analysis, are transfusion
independent, had resolution of eczema, and have experienced com-
plete immune reconstitution. With these patients, we have demon-
strated that rapid hematopoietic engraftment and complete immune
reconstitution can be achieved with limited toxicity in patients with
WASwho receive a reduced intensity conditioning followed by a T-
and B-cell depleted haploidentical graft with specific T-cell add
back.212
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Objectives: The role of allogeneic stem cell transplantation
(SCT) in paediatric acute myeloid leukaemia (AML) remains con-
troversial. SCT has generally been advocated for poor risk disease
in first complete remission (CR), the majority of patients following
relapse, and as a last resort in refractory disease.Methods: Twelve
consecutive patients (median age 2.2 years) underwent SCT for
high risk AML between 2000 and 2006. Patient and graft character-
istics are shown in the table.
Conditioning regimen consisted of busulphan (Bu) 16 mg/Kg,
cyclophosphamide (Cy) 120 mg/Kg, melphalan (Mel) 140 mg/m2;
alemtuzumab 1 mg/Kg was added in the unrelated donor setting.
Immunotheraputic strategies were employed to maximise a graft-
versus-leukaemia (GVL) response escalating through a reducedPatient
Age at
SCT
FAB
type Antecedent Cytogenetics
Disease
phase Donor type
GVHD
prophylaxis
1 2.0 M6 3q del, trisomy 21 CR1 MMUD alemtuzumab
CSA MTX
2 2.2 M7 complex CR1 MUD alemtuzumab
CSA MTX
3 1.7 M6 complex resistant
disease
MUD alemtuzumab
CSA MTX
4 2.7 M5 normal partial remission
after relapse
MMUD alemtuzumab
CSA MTX
5 1.6 M5 t(1;7)(q23;p22)
t(7;9;11)
CR2 MMUD alemtuzumab
CSA MTX
6 2.1 M0 t(7;12) CR2 MMUD alemtuzumab
CSA MTX
7 3.6 M7 normal partial remission
after relapse
MSD CSA
8 1.4 M0 normal partial remission
after relapse
MUD alemtuzumab
CSA MTX
9 5.7 secondary
AML
monosomy
7 trisomy 8
CR1 MMUD alemtuzumab
CSA MTX
10 2.4 M7 MDS monosomy 7 transformed
to AML
MSD CSA MTX
11 5.4 M2 MDS monosomy 7 transformed
to AML
MUD alemtuzumab
CSA MTX
12 2.2 M5 JMML del 9q transformed
to AML
MUD alemtuzumab
CSA MTXdose of alemtuzumab, early taper of cyclosporine A (CSA), donor
lymphocyte infusion (DLI) and treatment with alpha-interferon
(a-IFN). Results: All patients engrafted. Three out 5 patients un-
dergoing matched unrelated donor SCT, who were not in remis-
sion, received a 50% reduced dose of alemtuzumab. In 8 children
CSA was stopped early\ 2 months (n 5 4) and\ 3 months (n 5
4). Six of 12 patients developed acute graft versus host disease
(aGVHD), 3 grade 2, 3 grade 1. Five patients have developed lim-
ited chronic GVHD (cGVHD). In one patient who developed re-
cipient T-cell chimerism 2 months after SCT despite reduced
dose alemtuzumab and early taper of CSA, a DLI of 106/Kg was ad-
ministered followed by a-IFN. He developed grade 1 aGVHD and
the donor T cell chimerism increased to 80% but he never achieved
full donor haemopoiesis and relapsed 17 months after SCT. In an-
other patient, who developed noGVHDdespite cessation of CSA at
day 32, a-IFN was administered: he developed grade 1 aGVHD
evolving to limited cGVHD and remains in remission at 9 months.
Ten of 12 (83%) patients are alive in CR at amedian of 33months
(range 9–80) from SCT. There was no transplant related mortality,
but two patients relapsed 3 and 17 months after SCT and subse-
quently died. Conclusion: This early promising data suggests
that the combination of Bu Cy Mel should be studied further as
a conditioning regimen in children with high risk AML. Given
the substantial risk of relapse, and in the absence of GVHD, this ap-
proach should be used as a platform for escalating immunothera-
peutic strategies with the endpoint of sustaining 100% donor
chimerism or achieving non severe GVHD to maximize the poten-
tial for a GVL effect.213
A NOVEL NON-MYELOABLATIVE CONDITIONING REGIMEN FOLLOWED
BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
PEDIATRIC PATIENTS WITH NON-MALIGNANT HEMATOLOGICAL DIS-
ORDERS
Hussein, A.A., Rihani, R., Rahman, F.A., Helalah, O.A., Taani, H.A.,
Nserat, T.A.L., Sarhan, M.M. King Hussein Cancer Center, Amman,
Jordan.
Purpose: To evaluate the efficacy of using a novel non-myeloa-
blative conditioning regimen followed by allogenic hematopoietic
stem cell transplantation (HSCT) for pediatric patients with non-
malignant hematological disorders.Paptients andMethods:Eight
patients less than 18 years of age with benign hematological diseases
and high risk features were transplanted fromHLA identical related
donors between October, 2004 and August, 2007. Six patients had
sever thalassemia major, one patient had sickle cell anemia and
one had pure red cell aplasia. Seven were males and one female.Me-
dian age was 12 years (5–16). All patients had high serum ferritin
(1500–6000 ng/mL). All patients had significant palpable hepato-
megaly (4–8 cm). Four patients had hepatitis C infection, 6 patients
had grade II-III hepatic fibrosis on liver biopsy and one patient had
uncontrolled Nephrotic syndrome.
All patients received non-ablative conditioning regimen con-
sisted of: Busulphan (2 mg/kg twice daily for two days), Fludarabine
(35 mg/m2/day for 5 days), Horse ATG (30 mg/kg/day for 5 days)
and total lymphoid irradiation (500 cGy onDay zero). Cyclosporine
and oral Mycophenolate Mofetil were used as Graft versus Host
Disease (GvHD) prophylaxis. Six patients received mobilized pe-
ripheral stem cells while two patients received G-CSF primed
bone marrow cells. Results: After a median follow up of 13 months
(2–36), all patients are alive and doing well with no blood transfu-
sion requirement. Mean CD34 graft dose was 4.4 106/kg. All pa-
tients showed primary neutrophil engraftment at a median of 19
days (12–24). Four patients have sustained full donor chimerim,
while 3 patients have stable mixed donor chimerism (52–94%),
only one patient had graft failure 10 months after HSCT and he
is now doing well with full donor chimerism 20 months following
second non-ablative transplantation.
No patient required ICU admission post transplantation. Four
patients developed acute veno-oclusive disorder within first 30
days after HSCT; all were salvaged with supportive treatment.
Three patients had Grade II-III acute GvHD. Two patients had
Grade I-II chronic GvHD. Two patients developed posterior
